Incyte Corporation (NASDAQ:INCY) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Adjust Comment Print

Other large investors also recently modified their holdings of the company.

Obermeyer Wood Investment Counsel Lllp continued to hold its stake in shares of Incyte Co.

The stock decreased 0.12% or $0.11 during the last trading session, reaching $93.6. About 574,547 shares traded. (NASDAQ:CBRL) has risen 11.16% since December 6, 2016 and is uptrending. It has outperformed by 56.14% the S&P500. Following the sale, the director now directly owns 302,976 shares of the company's stock, valued at $45,058,590.72. The Cooke & Bieler Lp holds 806,128 shares with $22.44 million value, up from 731,209 last quarter. About 6.53 million shares traded or 86.38% up from the average. Signature Bank (NASDAQ:SBNY) has risen 4.47% since December 6, 2016 and is uptrending. It has underperformed by 18.19% the S&P500. Salem Inv Counselors holds 10 shares or 0% of its portfolio. Therefore 83% are positive. BMO Capital Markets reaffirmed an "outperform" rating and set a $172.00 price target on shares of Incyte in a research report on Monday, August 28th. As per Wednesday, August 12, the company rating was downgraded by Zacks. The rating was maintained by RBC Capital Markets with "Outperform" on Wednesday, February 15. Incyte Co. The firm's market capitalization is $26.93 billion. The stock has "Outperform" rating by BMO Capital Markets on Thursday, April 7. They issued a "buy" rating and a $160.00 target price for the company. The firm has "Buy" rating given on Tuesday, August 18 by Vetr. The firm has "Overweight" rating by Barclays Capital given on Wednesday, August 10.


Analysts await Signature Bank (NASDAQ:SBNY) to report earnings on January, 18. They expect $-0.47 earnings per share, down 413.33 % or $0.62 from last year's $0.15 per share. After $2.29 actual EPS reported by Signature Bank for the previous quarter, Wall Street now forecasts -2.62% negative EPS growth.

Investors sentiment decreased to 1.02 in 2017 Q2. Its down 0.39, from 1.41 in 2017Q1. It is negative, as 57 investors sold Incyte Corporation shares while 158 reduced holdings. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Incyte by 1.7% in the fourth quarter. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. Artal Grp owns 400,000 shares for 0.88% of their portfolio. Thomas J Herzfeld Advsrs reported 0.01% of its portfolio in Incyte Corporation (NASDAQ:INCY). Symphony Asset Mngmt Ltd Limited Liability Company invested 0.03% of its portfolio in Incyte Corporation (NASDAQ:INCY). The Texas-based United Automobile Association has invested 0.05% in Incyte Corporation (NASDAQ:INCY). Point72 Asset Ltd Partnership has invested 0.01% in Incyte Corporation (NASDAQ:INCY). 475.65 million shares or 0.25% less from 476.86 million shares in 2017Q1 were reported. More interesting news about Incyte Corporation (NASDAQ:INCY) were released by: Seekingalpha.com and their article: "Incyte: Depressed Valuation With Catalysts Coming" published on December 02, 2017 as well as Forbes.com's news article titled: "Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte" with publication date: November 28, 2017. State Street Corporation reported 7.51M shares. Cornerstone Advisors Inc holds 884 shares. Commonwealth Of Pennsylvania School Empls Retrmt Sys reported 0.02% stake. Fund Management has 9,828 shares. Susquehanna Group Llp accumulated 35,760 shares. The fund owned 38,200 shares of the biopharmaceutical company's stock after purchasing an additional 2,659 shares during the quarter. Princeton Strategies Ltd Liability reported 0.06% in Incyte Corporation (NASDAQ:INCY).

Since June 12, 2017, it had 0 insider buys, and 1 sale for $1.95 million activity. 16,756 shares were sold by GRYSKA DAVID W, worth $1.95M. This is an increase of 296% compared to the average daily volume of 1,495 call options. Its down 0.60, from 1.32 in 2017Q1. It improved, as 39 investors sold PPL shares while 215 reduced holdings. Howard Hughes Medical Institute raised its stake in shares of Incyte by 42.2% in the first quarter. Axa reported 272,845 shares. Fred Alger Management Inc stated it has 1.16 million shares or 0.7% of all its holdings.


The stock decreased 0.12% or $0.11 during the last trading session, reaching $93.6. Capital Ca reported 9,600 shares. Highland Mgmt Ltd holds 0.04% or 4,035 shares in its portfolio. Peak6 Limited Partnership reported 0.03% stake. Cibc World Inc, Ontario - Canada-based fund reported 51,417 shares. Pittenger And Anderson invested in 0.15% or 40,175 shares. Teacher Retirement System Of Texas stated it has 4,855 shares.

Among 13 analysts covering PPL Corporation (NYSE:PPL), 5 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. Finally, Goldman Sachs Group initiated coverage on Incyte in a report on Friday, October 6th. The rating was maintained by UBS on Wednesday, August 5 with "Buy". The rating was initiated by Cowen & Co on Wednesday, July 20 with "Outperform". The company was upgraded on Thursday, September 29 by Raymond James. On Thursday, October 12 the stock rating was maintained by BMO Capital Markets with "Buy". The stock has "Buy" rating by Keefe Bruyette & Woods on Monday, June 5. Brean Capital maintained the shares of INCY in report on Friday, February 12 with "Buy" rating.


Comments